Qian MJ - Search Results

1

cGAS and cancer therapy: a double-edged sword.

Du JM, Qian MJ, Yuan T, Chen RH, He QJ, Yang B, Ling Q, Zhu H. Du JM, et al. Among authors: qian mj. Acta Pharmacol Sin. 2022 Sep;43(9):2202-2211. doi: 10.1038/s41401-021-00839-6. Epub 2022 Jan 18. Acta Pharmacol Sin. 2022. PMID: 35042992 Free PMC article. Review.

2

The posttranslational modifications of Hippo-YAP pathway in cancer.

Yan F, Qian M, He Q, Zhu H, Yang B. Yan F, et al. Biochim Biophys Acta Gen Subj. 2020 Jan;1864(1):129397. doi: 10.1016/j.bbagen.2019.07.006. Epub 2019 Jul 12. Biochim Biophys Acta Gen Subj. 2020. PMID: 31306710 Review.

3

Deubiquitinating enzyme USP10 promotes hepatocellular carcinoma metastasis through deubiquitinating and stabilizing Smad4 protein.

Yuan T, Chen Z, Yan F, Qian M, Luo H, Ye S, Cao J, Ying M, Dai X, Gai R, Yang B, He Q, Zhu H. Yuan T, et al. Mol Oncol. 2020 Jan;14(1):197-210. doi: 10.1002/1878-0261.12596. Epub 2019 Nov 27. Mol Oncol. 2020. PMID: 31721429 Free PMC article.

4

USP10 Promotes Proliferation of Hepatocellular Carcinoma by Deubiquitinating and Stabilizing YAP/TAZ.

Zhu H, Yan F, Yuan T, Qian M, Zhou T, Dai X, Cao J, Ying M, Dong X, He Q, Yang B. Zhu H, et al. Cancer Res. 2020 Jun 1;80(11):2204-2216. doi: 10.1158/0008-5472.CAN-19-2388. Epub 2020 Mar 26. Cancer Res. 2020. PMID: 32217697

5

Targeting post-translational modification of transcription factors as cancer therapy.

Qian M, Yan F, Yuan T, Yang B, He Q, Zhu H. Qian M, et al. Drug Discov Today. 2020 Aug;25(8):1502-1512. doi: 10.1016/j.drudis.2020.06.005. Epub 2020 Jun 12. Drug Discov Today. 2020. PMID: 32540433

6

Post-translational modification of KRAS: potential targets for cancer therapy.

Wang WH, Yuan T, Qian MJ, Yan FJ, Yang L, He QJ, Yang B, Lu JJ, Zhu H. Wang WH, et al. Among authors: qian mj. Acta Pharmacol Sin. 2021 Aug;42(8):1201-1211. doi: 10.1038/s41401-020-00542-y. Epub 2020 Oct 21. Acta Pharmacol Sin. 2021. PMID: 33087838 Free PMC article. Review.

7

The calcimimetic agent cinacalcet inhibits hepatocellular carcinoma via YAP/TAZ suppression.

Zheng L, Du J, Ge F, Qian M, Yang B, He Q, Weng Q, Zhu H. Zheng L, et al. Pharmazie. 2021 Oct 1;76(10):511-514. doi: 10.1691/ph.2021.1646. Pharmazie. 2021. PMID: 34620281

8

Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression.

Qian M, Yan F, Wang W, Du J, Yuan T, Wu R, Zhao C, Wang J, Lu J, Zhang B, Lin N, Dong X, Dai X, Dong X, Yang B, Zhu H, He Q. Qian M, et al. Acta Pharm Sin B. 2021 Dec;11(12):4008-4019. doi: 10.1016/j.apsb.2021.04.003. Epub 2021 Jun 25. Acta Pharm Sin B. 2021. PMID: 35024322 Free PMC article.

9

SDHA/B reduction promotes hepatocellular carcinoma by facilitating the deNEDDylation of cullin1 and stabilizing YAP/TAZ.

Yuan T, Zhou T, Qian M, Du J, Liu Y, Wang J, Li Y, Fan G, Yan F, Dai X, Li X, Wu Y, Dong X, He Q, Zhu H, Yang B. Yuan T, et al. Hepatology. 2023 Jul 1;78(1):103-119. doi: 10.1002/hep.32621. Epub 2022 Jul 6. Hepatology. 2023. PMID: 35713976

10

The molecular mechanisms and targeting strategies of transcription factors in cholangiocarcinoma.

Wang J, Ge F, Yuan T, Qian M, Yan F, Yang B, He Q, Zhu H. Wang J, et al. Expert Opin Ther Targets. 2022 Sep;26(9):781-789. doi: 10.1080/14728222.2022.2137020. Epub 2022 Oct 19. Expert Opin Ther Targets. 2022. PMID: 36243001 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

31 results

Search Page

Filters